Chennuru, S., Koduri, J. and Baumann, M.A. (2008) Risk Factors for Symptomatic Hypocalcaemia Complicating Treatment with Zoledronic Acid. Internal Medicine Journal, 38, 635-637.
https://doi.org/10.1111/j.1445-5994.2007.01580.x

has been cited by the following article:

• TITLE: Severe and Prolonged Hypocalcaemia Post Zoledronic Acid Infusion in a Patent with Sleeve Gastrectomy

  AUTHORS: Andrew Jeyaruban, Bruce Hall

  KEYWORDS: Hypocalcaemia, Zoledronic Acid, Bariatric Surgery

  JOURNAL NAME: Journal of Biosciences and Medicines, Vol.10 No.9, September 21, 2022

  ABSTRACT: Background: Zoledronic acid is commonly used to treat hypercalcaemia and osteoporosis, as well as to prevent skeletal complications from haematological and solid organ malignancies. Case presentation: We report the case of a 38 year old lady who presented with severe hypocalcaemia following the administration of zoledronic acid. Her significant background history included vitamin D deficiency and sleeve gastrectomy three years ago. She had prolonged hypocalcaemia requiring IV calcium replacement for two months. Her prolonged hypocalcaemia was attributed to her vitamin D deficiency at the time of zoledronic acid infusion as well as her history of bariatric surgery. Conclusion: This case emphasises the importance of ensuring vitamin D levels are replete prior to zoledronic acid infusion and ensuring the calcium levels are checked frequently in patients with a history of bariatric surgery obtaining zoledronic acid.